Results 231 to 240 of about 77,108 (288)

Health-Related Quality of Life in the Era of Immune Checkpoint Blockade: What Do Patient-Reported Outcomes Reveal? [PDF]

Cancers (Basel)
Dunker AM, Malik N, Krause KJ, Keung EZ, Liu JB, Nassif Haddad EF, Somaiah N, Lyu HG, Roland CL.   +8 more
europepmc   +1 more source

Combined Immunotherapy in Treating Patients with Advanced Hepatocellular Carcinoma. [PDF]

Biomedicines
Li KHL, Leung R, Li BCW, Cheung TT, Yau T.   +4 more
europepmc   +1 more source

Discrepant CD3+ TILs in PD-L1-Negative NSCLC: Favorable Outcome in an Elderly Patient Treated With Nivolumab, Ipilimumab, and Chemotherapy. [PDF]

Am J Case Rep
Sekiya M, Nakatsugawa M, Koyama N, Kajiwara N, Aoki T.   +4 more
europepmc   +1 more source

Efficacy and Pulmonary Outcomes of Dual Immunotherapy Plus Chemotherapy Versus Standard Chemotherapy in Advanced Non-small Cell Lung Cancer. [PDF]

Cureus
Forero Vásquez BN, Dunay Silva AAA, Hernández Cedeño JS, Salinas Lucero DA, Acevedo Carrion GA, Perez-Correa JF, Salazar Nieto IB.   +6 more
europepmc   +1 more source

Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial. [PDF]

Nat Commun
Ray-Coquard I, Kaminsky-Forrett MC, Ohkuma R, de Montfort A, Joly F, Treilleux I, Ghamry-Barrin S, Bello-Roufai D, Saintigny P, Angelergues A, Michon L, Hardy-Bessard AC, Attignon V, Auclair J, Chemin G, Lainé A, Péré H, Veyer D, Savoye AM, Berthet J, Caux C, Lecuru F, Dubois B, Bétrian S.   +23 more
europepmc   +1 more source

A systematic review of the applications of the real option value of medical technologies in oncology. [PDF]

J Manag Care Spec Pharm
Adjei K, Diaby V, Li M, Sherbeny F, Suther S, Ali AA.   +5 more
europepmc   +1 more source

Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer. [PDF]

Nat Commun
Lei M, Overman MJ, Yao J, André T, Lonardi S, Lenz HJ, Aglietta M, Gelsomino F, McDermott R, Wong KYM, Morse MA, Van Cutsem E, Hendlisz A, Cardin DB, Neyns B, Hill A, Krishnamurthy A, Chen F, Kochuparambil S, Jenq RR, Abdullaev S, He B, Novosiadly R, Kopetz S.   +23 more
europepmc   +1 more source

Immune checkpoint inhibitor-associated aseptic meningitis: a pharmacovigilance study using the FDA adverse event reporting system (2011-2024). [PDF]

Front Immunol
Guo H, Pang Y, Guo Q, Wang Z, Wang H.
europepmc   +1 more source

CIK-augmented anti-PD1/CTLA4 immunotherapy eradicates chemo-resistant ovarian cancer via tripartite mechanistic synergy. [PDF]

Front Oncol
Chen P, Pan J, Chen L, Feng X.
europepmc   +1 more source

Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study. [PDF]

Int J Urol
Sazuka T, Tatsugami K, Shirotake S, Hamamoto S, Nozawa M, Numakura K, Mizokami A, Kondo T, Naito S, Abe T, Ohba K, Kimura G, Onodera S, Yamaguchi K, Uemura H.   +14 more
europepmc   +1 more source